Prolia is a brand-name drug that contains denosumab, which is used to treat osteoporosis and other bone-related conditions. Biosimilars are drugs that are similar to Prolia and have the same active ingredient, denosumab. According to the sources provided, the potential side effects of Prolia biosimilars are similar to those of Prolia itself.

The most common side effects of Prolia are back pain, pain in the arms and legs, high cholesterol levels, and urinary tract infections. Some patients may also experience skin reactions, such as rashes and itching. In rare cases, Prolia can cause more serious side effects, such as severe infections, low calcium levels, and jaw problems.

Since Prolia biosimilars contain the same active ingredient as Prolia, it is likely that they will have similar side effects. However, the exact side effects of each biosimilar may vary depending on the specific formulation and manufacturing process.

It is important to note that biosimilars are rigorously tested and approved by regulatory agencies, such as the US Food and Drug Administration (FDA), before they are made available to the public. These tests ensure that biosimilars are safe and effective for their intended use.

In summary, the potential side effects of Prolia biosimilars are likely to be similar to those of Prolia itself, which include back pain, pain in the arms and legs, high cholesterol levels, and urinary tract infections. Patients should be aware of these potential side effects and talk to their healthcare provider if they experience any symptoms while taking Prolia or a biosimilar.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/PROLIA
[2] https://www.medicalnewstoday.com/articles/prolia
[3] https://www.novartis.com/news/media-releases/sandoz-biologics-license-application-proposed-biosimilar-denosumab-accepted-us-fda